IMC Chicago
MLTX icon

IMC Chicago’s MoonLake Immunotherapeutics MLTX Stock Holding History

IMC Chicago’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.29M Buy
69,100
+1,600
+2% +$26.5K ﹤0.01% 3017
2025
Q4 		$890K Buy
67,500
+13,100
+24% +$155K ﹤0.01% 3071
2025
Q3 		$390K Buy
+54,400
New +$2.84M ﹤0.01% 3310

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

IMC Chicago's MLTX Position: Q1 2026 in Review

IMC Chicago reduced its MoonLake Immunotherapeutics (MLTX) stake by 69% in Q1 2026, selling an estimated $416K and leaving 11,352 shares worth $212K. The position accounts for ﹤0.01% of the portfolio, ranked #4958.

IMC Chicago first reported a position in MLTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $481K in Q4 2025. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • IMC Chicago held 11,352 shares of MoonLake Immunotherapeutics worth $212K as of Q1 2026.
  • IMC Chicago sold 25,116 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $416K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of IMC Chicago's portfolio in Q1 2026, its #4958 holding.
  • IMC Chicago first reported a position in MoonLake Immunotherapeutics in Q4 2025 and has held it in 2 quarters since.
  • IMC Chicago's MoonLake Immunotherapeutics position peaked at $481K in Q4 2025.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.